Immuno-Oncology | Specialty

PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer

December 1st 2016

Identifying Bone Progression in Metastatic Prostate Cancer and Treatment Options

December 1st 2016

Immunotherapy and the Abscopal Effect in Treating Metastatic Prostate Cancer

December 1st 2016

Radium-223 Alone and with Other Agents for Prostate Cancer

December 1st 2016

FDA-approved Indications for Treatment Versus Use in Current Clinical Trials

December 1st 2016

Clinical Trials in Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

Challenges in Treating Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

Decisions on Choosing LHRH Agonists for Treating Prostate Cancer

December 1st 2016

Use of LHRH Agonists Versus Antagonists in Prostate Cancer

December 1st 2016

Multidisciplinary Approach and Role of PSA and Testosterone Monitoring in Prostate Cancer

December 1st 2016

Intermittent versus Continuous Androgen-Deprivation Therapy in Prostate Cancer

December 1st 2016

Advanced Imaging Techniques for Prostate Cancer

December 1st 2016

Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate Cancer

December 1st 2016

IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma

November 30th 2016

The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.

Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer

November 30th 2016

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Checkpoint Inhibitors Changing Landscape for Advanced Solid Tumors

November 29th 2016

Immunotherapy continues to be one of the fastest-evolving fields in oncology. In recent years, numerous immunotherapies have shown good efficacy, safety, and durability across many tumor types, including some advanced solid tumors that have not seen meaningful treatment developments in decades.

Taking Steps to Manage Adverse Events Associated with Checkpoint Inhibitors

November 29th 2016

The observed adverse events that have been associated with immunotherapy, especially immunotherapy combinations, have to be properly assessed against their clearly improved efficacy in patients with otherwise dismal prognosis from stage IV cancers.

FDA Grants Priority Review to Avelumab for Merkel Cell Carcinoma

November 29th 2016

The FDA has granted a priority review to a biologics license application for avelumab as a treatment for patients with metastatic Merkel cell carcinoma.

FDA Grants Priority Review to Pembrolizumab for MSI-H Cancer

November 29th 2016

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced microsatellite instability-high cancer.

EC Approves Nivolumab for Hodgkin Lymphoma

November 23rd 2016

The European Commission has approved nivolumab for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.